💊Takeda Announces Intention to Acquire TiGenix
Acquisition Highlights
Deal reinforces Takeda’s commitment to patients living with Inflammatory Bowel Disease (IBD), an area of high unmet medical need
Acquisition extends existing collaboration between Takeda and TiGenix to develop and commercialize Cx601 (darvadstrocel)
https://www.takeda.com/newsroom/newsreleases/2018/takeda-announces-intention-to-acquire-tigenix/